ANAPTYSBIO INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
ANAB$48.38+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net loss | $(163,619) | $(128,724) | $(57,796) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 652 | 675 | 619 |
| Stock-based compensation | 33,205 | 27,356 | 15,347 |
| Accretion/amortization of investments, net | (10,521) | (2,507) | 493 |
| Amortization of right-of-use assets – operating | 1,724 | 1,660 | 1,471 |
| Non-cash interest expense | 18,083 | 21,108 | 1,450 |
| Gain on disposal of property and equipment | — | — | (15) |
| Changes in operating assets and liabilities: | |||
| Receivables from collaborative partners | (5,432) | (543) | (876) |
| Prepaid expenses and other assets | (4,194) | (813) | (1,801) |
| Accounts payable and other liabilities | 10,938 | 9,700 | (4,740) |
| Operating lease liabilities | (1,636) | (1,505) | (72) |
| Net cash used in operating activities | (120,800) | (73,593) | (45,920) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Purchase of investments | (303,919) | (802,503) | (118,662) |
| Sales and maturities of investments | 449,480 | 408,016 | 158,848 |
| Proceeds from the sale of property and equipment | — | — | 15 |
| Purchases of property and equipment | (807) | (358) | (1,366) |
| Net cash provided by (used in) investing activities | 144,754 | (394,845) | 38,835 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Proceeds from issuance of common stock | 2,472 | 11,827 | 2,553 |
| Proceeds from the sale of future royalties | — | 35,000 | 250,000 |
| Repayment of liability for sale of future royalties | (11,726) | (2,474) | — |
| Payments for repurchase of common stock | (50,000) | — | — |
| Payments for issuance costs related to the sale of future royalties | (43) | (336) | (255) |
| Net cash (used in) provided by financing activities | (59,297) | 44,017 | 252,298 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (35,343) | (424,421) | 245,213 |
| Cash, cash equivalents and restricted cash, beginning of period | 71,308 | 495,729 | 250,516 |
| Cash, cash equivalents and restricted cash, end of period | $35,965 | $71,308 | $495,729 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |||
| Non-cash investing and financing activities: | |||
| Leased assets obtained in exchange for operating lease liabilities | $— | $— | $20,685 |
| Amounts accrued for property and equipment | $8 | $154 | $31 |
| Amounts accrued for issuance costs related to the sale of future royalties | $— | $80 | $102 |
| Amounts accrued for repurchase of common stock | $456 | $— | $— |
| Receivable related to issuance of common stock, upon exercise of stock options | $(51) | $40 | $11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.